Alan Pestronk, MD
Neurology · Saint Louis, MONPI 1043236359
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 3 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Pfizer. That places this record below the midpoint for neurology clinicians in MO, where the typical reported total is $933.
Across 3 payments — averaging $16.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$49
Across 145 payments — averaging $4990.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amicus Therapeutics, Inc.$391K
- Sanofi$166K
- Argenx US, Inc.$88K
- Genentech, Inc.$33K
- UCB SA$33K
- E.r. Squibb & Sons, L.L.C.$8K
- plus $5K from 2 others
What the payments were for
- Food & beverage$49100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 3 | $49 |
How this compares
$49 in reported general payments places this provider in the 10th percentile of 381 neurology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EvrysdiRisdiplam | 59 | $1,747,355 |
| SkyclarysOmaveloxolone | 11 | $355,577 |
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 30 | $275,645 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $207,371 |
| Fentanyl | 19 | $4,258 |
| Gabapentin | 31 | $1,119 |
| Pyridostigmine Bromide | 23 | $954 |
| Pregabalin | 25 | $608 |
| Prednisone | 66 | $505 |
| Duloxetine Hcl | 17 | $340 |
| Oxycodone Hcl | 12 | $324 |
| Nortriptyline Hcl | 18 | $174 |
| Tramadol Hcl | 20 | $105 |
Paid to pharmacies, not to this prescriber.
Other neurology in Saint Louis
- Barry SingerSaint Louis$1.9M
- Mark TullmanSaint Louis$1.5M
- Robert NaismithSaint Louis$677K
- Arun VaradhacharySaint Louis$273K
- Anne CrossSaint Louis$190K
- David HoltzmanSaint Louis$165K
- Ghazala HayatSaint Louis$155K
- Pratap ChandSaint Louis$139K
- Lee TempelSaint Louis$121K
- Salim ChahinSaint Louis$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.